Foundation Medicine (FMI) Stock Price, News & Analysis

Company Overview

Foundation Medicine, Inc. provides various molecular information products in the United States. The company's molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic insights about each patient's individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted therapies and immunotherapies. It provides clinical products, such as FoundationOne for solid tumors; FoundationOne Heme for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and sarcomas; Foundation Assay for Circulating Tumor; FoundationFocus CDxBRCA, a diagnostic assay to aid in identifying women with ovarian cancer; and FoundationOne CDx, a diagnostic assay for solid tumors. The company also offers FoundationCORE, a knowledgebase to publish scientific and medical advances, and foster relationships throughout the oncology community. In addition, it has strategic collaboration agreements with F. Hoffmann-La Roche Ltd.; and Genentech, Inc. Foundation Medicine, Inc. has a collaboration with The European Organisation for Research and Treatment of Cancer to advance precision medicine using comprehensive genomic profiling to facilitate clinical trial enrollment. It also has a three-party collaboration agreement with F. Hoffmann-La Roche Ltd and DIAN Diagnostics Group, Co., Ltd. to integrate the company's comprehensive genomic profiling assays into clinical patient care in mainland China. The company was founded in 2009 and is headquartered in Cambridge, Massachusetts. Foundation Medicine, Inc. is a subsidiary of Roche Holdings, Inc.

Key Stats

• Today's Range: $137.00 to $137.00
• 50-Day Range: N/A
• 52-Week Range: $31.70 to $137.20
• Volume: N/A
• Average Volume: 621,352 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

FMI Stock Analysis - Frequently Asked Questions

How were Foundation Medicine's earnings last quarter?

Foundation Medicine, Inc. (NASDAQ:FMI) announced its quarterly earnings data on Wednesday, May, 2nd. The company reported ($1.02) EPS for the quarter, beating analysts' consensus estimates of ($1.10) by $0.08. Foundation Medicine's revenue for the quarter was up 100.7% on a year-over-year basis.

What other stocks do shareholders of Foundation Medicine own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Foundation Medicine investors own include Corbus Pharmaceuticals (CRBP), Visa (V), Gilead Sciences (GILD), Bristol Myers Squibb (BMY), NVIDIA (NVDA), HP (HPQ) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 5/02/2018
• Today: 7/13/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Laboratories
• Sub-Industry: N/A
• Current Symbol: NASDAQ:FMI
• CIK: 1488613
• Web: www.foundationmedicine.com
• Phone: 617-418-2200
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Optionable
• Beta: N/A